Joyce Chuen, PA
Medical · Argyle, TXNPI 1548810476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 35.8% of the total. Reporting peaked in 2023 at $641 and has fallen 93.9% since, to $39 in 2025.
Across 105 payments — averaging $14.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$529
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$201
- Otsuka America Pharmaceutical, Inc.$80
- Lundbeck LLC$73
- Tris Pharma Inc$69
- Lilly USA, LLC$59
- plus $467 from 16 others
What the payments were for
- Food & beverage$1,478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $529 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $201 |
| Otsuka America Pharmaceutical, Inc. | 5 | $80 |
| Lundbeck LLC | 4 | $73 |
| Tris Pharma Inc | 3 | $69 |
| Lilly USA, LLC | 4 | $59 |
| Johnson & Johnson | 3 | $49 |
| GSK | 2 | $46 |
| AstraZeneca | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Novo Nordisk | 3 | $36 |
| Novartis | 2 | $34 |
| Astellas Pharma US Inc | 2 | $30 |
| Amgen | 2 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $27 |
| Pfizer | 1 | $25 |
| Merck | 2 | $24 |
| Corium, LLC | 2 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
| Genentech USA, Inc. | 1 | $9 |
How this compares
$1,478 in reported general payments places this provider in the 60th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 16 | $435 |
| Omeprazole | 12 | $383 |
| Atorvastatin Calcium | 34 | $365 |
| Gabapentin | 19 | $361 |
| Levothyroxine Sodium | 38 | $282 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $232 |
| Allopurinol | 15 | $188 |
| Tamsulosin Hcl | 11 | $159 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $143 |
| Montelukast Sodium | 13 | $131 |
| Rosuvastatin Calcium | 16 | $117 |
| Metformin Hcl | 13 | $92 |
| Trazodone Hcl | 12 | $89 |
| Pantoprazole Sodium | 14 | $88 |
| Losartan Potassium | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Other medical in Argyle
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.